REDWOOD CITY, Calif., July 7, 2026
LTZ Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for LTZ-232, allowing the company to begin clinical evaluation of its investigational therapy in patients with advanced metastatic colorectal cancer (mCRC) and other EpCAM-positive solid tumors. The clearance marks an important milestone for the clinical-stage immunotherapy company, as LTZ-232 becomes the second product candidate from its proprietary Universal Myeloid Cell Engager (U-MCE™) Platform to advance into human clinical trials. The company plans to initiate a Phase 1 open-label, multicenter clinical study during the fourth quarter of 2026, expanding its development strategy beyond hematologic cancers into broader solid tumor indications. The investigational therapy is designed to address significant unmet medical needs in patients with difficult-to-treat cancers that have limited response to currently available immunotherapies.
Novel Myeloid Cell Engager Targets Immunologically Cold Solid Tumors
LTZ-232 is a first-in-class bispecific antibody engineered to activate tumor-associated macrophages (TAMs) and direct them to identify, engulf, and eliminate EpCAM-positive tumor cells through enhanced phagocytic activity. The therapy utilizes the company’s U-MCE™ Platform, which is designed to harness the innate immune system by redirecting myeloid cells toward tumor destruction. LTZ Therapeutics selected metastatic colorectal cancer as the initial clinical indication because of its consistent EpCAM expression and the presence of a myeloid-rich tumor microenvironment, despite the disease traditionally being considered an immunologically cold tumor with limited responsiveness to many existing immunotherapy approaches. The company noted that the clinical development program has been structured to allow future expansion into additional solid tumor indications where similar biological characteristics may support therapeutic benefit.
Preclinical Results Support Advancement into Human Studies
According to LTZ Therapeutics, LTZ-232 demonstrated potent anti-tumor activity across multiple in vitro and in vivo preclinical models, while also showing a favorable safety profile that supported regulatory advancement into clinical testing. Company founder and Chief Executive Officer Dr. Robert Li stated that progressing LTZ-232 into the clinic represents another major achievement for the company’s U-MCE™ Platform, highlighting its potential to address a wide range of cancers beyond its initial hematologic malignancy program. Chief Medical Officer Dr. William Grossman emphasized that patients with advanced metastatic colorectal cancer continue to face limited treatment options because many tumors fail to respond to conventional immunotherapies. He noted that the company’s differentiated approach aims to overcome these limitations by activating myeloid immune cells capable of driving anti-tumor responses within challenging tumor microenvironments, potentially extending the benefits of immunotherapy to patients with otherwise resistant cancers.
Advertisement
Second Clinical Candidate Strengthens LTZ Therapeutics’ Oncology Pipeline
The FDA clearance of LTZ-232 significantly expands LTZ Therapeutics’ clinical pipeline, complementing LTZ-301, which is already undergoing clinical evaluation for hematologic malignancies. Together, the programs demonstrate the company’s strategy of applying its proprietary Universal Myeloid Cell Engager Platform across multiple cancer types by leveraging distinct immune mechanisms to improve treatment outcomes. With the planned initiation of the Phase 1 clinical trial later this year, LTZ Therapeutics will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of LTZ-232 in patients with advanced metastatic colorectal cancer and other eligible EpCAM-positive solid tumors. Successful clinical development could establish LTZ-232 as a first-in-class myeloid engager immunotherapy, offering a novel therapeutic option for patients with difficult-to-treat solid tumors while further validating the company’s innovative immuno-oncology platform.
Source: LTZ Therapeutics, press release
